Since our derived E2F4 signature was selected with the intent of being relatively tissue-independent, consisting of genes that play a role in cell cycle progression across three cell lines, we decided to evaluate E2F4 in six other cancers: bladder cancer, colon cancer, lung cancer (NSCLC), brain cancer (glioblastoma), leukemia (AML) and Burkitt’s lymphoma. Here, E2F4 is linked to urinary bladder carcinoma.